Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2014

View Archived Issues

Bavarian Nordic presents novel RSV vaccines

Identification of small molecules that specifically target precursor microRNAs

Stem cell epigenetic DNA methylation signature for leukemia prognosis

QIAGEN launches careHPV Test in India

Bayer plans to acquire Dihon Pharmaceutical in China

EMA accepts tedizolid phosphate MAA for review

Anacor Pharmaceuticals completes end-of-phase II meeting with the FDA for AN-2728

QLT reports data from phase Ib trial of QLT-091001

Alzheimer's Drug Discovery Foundation funds research in gene therapy

AtheroNova reports preliminary phase I date for AHRO-001

Immune Design treats first patient in phase I trial of ID-G305

Salix Pharmaceuticals and RedHill Biopharma form exclusive agreement for RHB-106

Novel DNA-damaging quinone compounds disclosed by the University of Salford

La Jolla Pharmaceutical signs agreement with George Washington University for LJPC-501

Covidien closes its acquisition of Given Imaging

EMA accepts MAA filing for oritavancin

French investigators divulge novel compounds for cancer

Investigators prepare novel nanovesicles to stimulate healing

Forest Laboratories submits NDA to FDA for nebivolol/valsartan combination

U.S. researchers disclose new EGFRvIII-derived cancer vaccines

Astellas assumes full responsibility for isavuconazole in U.S. and Canada

Takeda seeks Japanese approval for TAK-438 for acid-related diseases

Rare Disease Day News: Adaptive licensing, EryDex shows benefit in ataxia telangiectasia

Cannabidol receives FDA orphan drug status for Lennox-Gastaut syndrome

FDA grants orphan drug status to pracinostat for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...